Daiichi Sankyo Gains Diabetes Indication For Cholesterol Drug WelChol
This article was originally published in The Pink Sheet Daily
Executive Summary
Therapy indicated as adjunctive treatment to improve glycemic control in type 2 diabetes patients.
You may also be interested in...
Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the merger of Daiichi and Sankyo, how the combined entity has evolved, and how the firm's Benicar/amlodipine combination Azor figures as a key growth driver going forward.
Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication
If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.